Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer

Cancer Science

Volumn 101, Issue 1, 2010, Pages 22-28

  Kawai, Koji ^a   Akaza, Hideyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; LACTATE DEHYDROGENASE; NEDAPLATIN; PACLITAXEL; SEROTONIN ANTAGONIST; VINBLASTINE; VINCRISTINE;

AGE DISTRIBUTION; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; GERM CELL TUMOR; HUMAN; INFECTION; LUNG TOXICITY; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NON SEMINOMATOUS GERMINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SALVAGE THERAPY; SEPSIS; SURVIVAL TIME; TESTIS CANCER; TESTIS CARCINOMA; TESTIS TUMOR; VISCERAL METASTASIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; ETOPOSIDE; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASMS, GERM CELL AND EMBRYONAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; RISK ASSESSMENT; SALVAGE THERAPY; TESTICULAR NEOPLASMS;

EID: 71849105159     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01373.x     Document Type: Review

References (79)

1. Levi F, La Vecchia C, Boyle P. Western and Eastern European trends in testicular cancer. Lancet 2001, 357:1853-1854.
2. Kolonel LN, Ross RK, Thomas DB. Epidemiology of testicular cancer in the Pacific Basin. Natl Cancer Inst Monogr 1982, 62:157-160.
3. Matsuda T, Saika K. Comparison of time trends in testicular cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents, Vols IV-VIII. Jpn J Clin Oncol 2008, 38:578-9.
4. Forman D, Moller H. Testicular cancer. Cancer Surv 1994, 20:323-341.
5. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003, 170:5-11.
6. Marugame T, Katanoda K, Matsuda T. The Japan cancer surveillance report: incidence of childhood, bone, penis and testis cancers. Jpn J Clin Oncol 2007, 37:319-23.
7. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977, 87:293-8.
8. Williams SD, Birch R, Einhorn LH. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987, 316:1435-1440.
9. Bajorin D, Katz A, Chan E. Comparison of criteria for assigning germ cell tumor patients to 'good risk' and 'poor risk' studies. J Clin Oncol 1988, 6:786-92.
10. Bosl GJ, Geller NL, Cirrincione C. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983, 43:3403-7.
11. Birch R, Williams S, Cone A. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 1986, 4:400-7.
12. Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours. Lancet 1985, 325:8-11.
13. Droz JP, Kramar A, Ghosn M. Prognostic factors in advanced nonseminomatous testicular cancer. A multivariate logistic regression analysis. Cancer 1988, 62:564-8.
14. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997, 15:594-603.
15. Kawai K, Hinotsu S, Oikawa T. Treatment outcome of metastatic testicular cancer at a single institution in Japan, a country with low incidence of germ cell tumor. Jpn J Clin Oncol 2006, 36:723-30.
16. Gerl A, Clemm C, Schmeller N. Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: a single-institution experience. Br J Cancer 1996, 74:1280-1285.
17. Pentheroudakis G, de Bono JS, Kaye SB. Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumors by optimizing combined treatment. BJU Int 2003, 92:36-42.
18. Murakami M, Hara I, Miyake H. Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: A single-institution experience. Int J Urol 2004, 11:768-773.
19. Shintaku I, Satoh M, Okajima E. Survival of metastatic germ cell cancer patients assessed by international germ cell consensus classification in Japan. Jpn J Clin Oncol 2008, 38:281-7.
20. Van Dijk MR, Steyerberg EW, Habbema JD. Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer 2006, 42:820-826.
21. Bosl GJ, Geller NL, Bajorin D. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 1988, 6:1231-8.
22. Einhorn LH, Williams SD, Loehrer PJ. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989, 7:387-91.
23. Horwich A, Sleijfer DT, Fosså SD. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997, 15:1844-52.
24. Bokemeyer C, Köhrmann O, Tischler J. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol 1996, 7:1015-21.
25. Loehrer PJ, Johnson D, Elson P. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995, 13:470-6.
26. de Wit R, Stoter G, Kaye SB. Importance of bleomycin in combination chemotherapy for good-prognosis testicular non-seminoma: A randomized study of the European Organization for Research and Treatment of Genitourinary Tract Cancer cooperative group. J Clin Oncol 1997, 15:1837-1843.
27. Toner GC, Stockler MR, Boyer MJ. Comparison of two standard chemotherapy regimens for good prognosis germ-cell tumours: a randomized trial. Lancet 2001, 357:739-745.
28. de Wit R, Roberts JT, Wilkinson PM. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001, 19:1629-40.
29. Kondagunta GV, Bacik J, Bajorin D. Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 2005, 23:9290-4.
30. Culine S, Kerbrat P, Kramar A. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol 2007, 18:917-24.
31. de Wit R, Stoter G, Sleijfer DT. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 1995, 71:1311-14.
32. Ozols RF, Ihde DC, Linehan WM. A randomized trial of standard chemotherapy vs a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 1988, 6:1031-40.
33. Nichols CR, Williams SD, Loehrer PJ. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991, 9:1163-72.
34. Nichols CR, Catalano PJ, Crawford ED. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998, 16:1287-93.
35. Kaye SB, Mead GM, Fossa S. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998, 16:692-701.
36. Hinton S, Catalano PJ, Einhorn LH. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 2003, 97:1869-75.
37. Culine S, Kramar A, Théodore C. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 2008, 26:421-7.
38. Droz JP, Kramar A, Biron P. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol 2007, 51:739-46.
39. Motzer RJ, Nichols CJ, Margolin KA. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 2007, 25:247-56.
40. Miki T, Mizutani Y, Akaza H. Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor. Int J Urol 2007, 14:54-9.
41. Schmoll HJ, Kollmannsberger C, Metzner B. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003, 21:4083-91.
42. Hartmann JT, Gauler T, Metzner B. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol 2007, 25:5742-7.
43. Christian JA, Huddart RA, Norman A. Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol 2003, 21:871-7.
44. Husband DJ, Green JA. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity. Eur J Cancer 1992, 28:86-91.
45. Miyanaga N, Akaza H, Hattori K. The importance of dose intensity in chemotherapy of advanced testicular cancer. Urol Int 1995, 54:220-5.
46. Krege S, Beyer J, Souchon R. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008, 53:497-513.
47. Kawai K, Ando S, Hinotsu S. Completion and toxicity of induction chemotherapy for metastatic testicular cancer: an updated evaluation of Japanese patients. Jpn J Clin Oncol 2006, 36:425-31.
48. Fosså SD, Kaye SB, Mead GM. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998, 16:716-24.
49. Simpson AB, Paul J, Graham J. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer 1998, 78:1061-1066.
50. Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med 1990, 11:1-20.
51. O'Sullivan JM, Huddart RA, Norman AR. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003, 14:91-96.
52. Kawai K, Hinotsu S, Akaza H. Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity. Jpn J Clin Oncol 1998, 28:546-550.
53. Ginsberg S, Comis RL. The pulmonary toxicity of antineoplastic agents. Semin Oncol 1982, 9:34-51.
54. Einhorn LH, Foster RS. Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: is there a preferred regimen? J Clin Oncol 2006, 24:2597-8.
55. Loehrer PJ, Einhorn LH, Williams SD. VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory germ cell cancer. J Clin Oncol 1986, 4:528-36.
56. McCaffrey JA, Mazumdar M, Bajorin DF. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 1997, 15:2559-2563.
57. Loehrer PJ, Gonin R, Nichols CR. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998, 16:2500-2504.
58. Motzer RJ, Bajorin DF, Schwartz LH. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994, 12:2277-2283.
59. Bokemeyer C, Beyer J, Metzner B. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996, 7:31-4.
60. Chou TC, Motzer RJ, Tong Y. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 1994, 86:1517-24.
61. Motzer RJ, Sheinfeld J, Mazumdar M. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000, 18:2413-2418.
62. Kondagunta GV, Bacik J, Donadio A. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005, 23:6549-55.
63. Mead GM, Cullen MH, Huddart R. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 2005, 93:178-84.
64. Kawai K, Miyazaki J, Tsukamoto S. Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer. Jpn J Clin Oncol 2003, 33:127-31.
65. Nonomura N, Oka D, Nishimura K. Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors. Int J Urol 2007, 14:527-31.
66. Nichols CR, Tricot G, Williams SD. Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989, 7:932-9.
67. Broun ER, Nichols CR, Kneebone P. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992, 117:124-8.
68. Einhorn LH, Williams SD, Chamness A. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007, 357:340-8.
69. Beyer J, Stenning S, Gerl A. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis. Ann Oncol 2002, 13:599-605.
70. Pico JL, Rosti G, Kramar A. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005, 16:1152-9.
71. Kondagunta GV, Bacik J, Sheinfeld J. Paclitaxel plus ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol 2007, 25:85-90.
72. Motzer RJ, Mazumdar M, Sheinfeld J. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000, 18:1173-80.
73. Miki T, Mizutani Y, Nonomura N. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer 2002, 95:1879-85.
74. Harding MJ, Paul J, Gillis CR. Management of malignant teratoma: does referral to a specialist unit matter? Lancet 1993, 341:999-1002.
75. Norum J, Nordoy T, Wist E. Testicular cancer treated in a minor general oncology department. Eur J Cancer 1995, 31A:293-295.
76. Collette L, Sylvester RL, Stenning SP. Impact of the treating institution on survival of patients with 'poor-prognosis' metastatic nonseminoma. J Natl Cancer Inst 1999, 91:839-846.
77. Flechon A, Bompas E, Biron P. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002, 168:1975-1979.
78. Debono D, Heilman DK, Einhhorn LH. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 1997, 15:1455-1464.
79. Oldenburg J, Alfsen GC, Lien HH. Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 2003, 21:3310-3317.